Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
GLP1 receptor agonists are the first class of medication to directly target these systems, and the results of preliminary studies are promising for a new way of treating both overeating and undereating that goes beyond merely addressing depression, weight, or individual food type preferences, although further research is still needed
The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]
(2017) 181:805.e1
For years, obesity rates in the US have gone in one direction: up
However, just medication alone isnt going to create lasting change
